从创新药到基因治疗、从诊断试剂到医疗器械，在广州，生物医药"黄埔军团"加速崛起。 12月15日，2025年广州独角兽创新企业榜单正式揭晓，全市共有210家企业入选。作为广州独角兽企业最密集的集聚地和广州科创"领头羊"，广州开发区、 黄埔区聚集了60家独角兽企业（占全市29%）。尤其在集成电路、生物医药、人工智能、新能源等领域形成产业集群，吸引了粤芯、艾佛光通、心航路、奥 动新能源等硬科技企业。 生物医药已经是黄埔区最鲜明的产业名片。就在12月12日，"广州开发区战略企业家培育计划——生物医药产业战略破局圆桌会"在黄埔区举办。自今年9月 以来，广州开发区、黄埔区就谋划启动"战略企业家培育计划"，有效整合政府、市场、专业机构等多方资源，通过系统化培育以提升企业竞争力和企业家经 营管理能力。 云舟生物就在此次圆桌会初步对接了从事不同环节的企业。云舟生物科技（广州）股份有限公司董事、执行总裁黄锐向智通财经表示，公司正在推进国际 化，更需要联合区内伙伴，共同打造"中国技术+全球市场"出海联合平台，而黄埔区开放、协同、互信的产业氛围，正是创新型企业所需要的发展土壤。 这家公司目前已发展为全球最大规模的科研级别基因载体CR ...

Core Viewpoint - The article highlights the innovative approach of Yunzhou Biotech in revolutionizing the production and design of gene vectors, addressing significant inefficiencies in the life sciences research sector and extending its services from research to clinical applications [1][10][12]. Group 1: Background and Challenges - The inception of Yunzhou Biotech stemmed from a challenge faced by researchers in constructing gene vectors, which often took months to ensure quality [2][4]. - The founder, Dr. Lantian, recognized that the lack of reliable suppliers for gene vectors led to a systemic inefficiency in the industry, consuming valuable time and resources [4][6]. Group 2: Innovative Solutions - Dr. Lantian proposed a modular and standardized approach to gene vector construction, akin to assembling with LEGO blocks, allowing researchers to select components from a library of over ten thousand functional elements [6][9]. - The launch of the VectorBuilder platform in 2015 marked a significant advancement, enabling users to design and order custom gene vectors with minimal expertise, thus freeing them from repetitive tasks and enhancing research efficiency [9][10]. Group 3: Business Expansion and Clinical Applications - Yunzhou Biotech has expanded its services from basic research to include Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO) services, creating a comprehensive service chain from research to commercialization [11][12]. - The company has successfully delivered over 300 batches of customized clinical-grade plasmids and viral vectors, with more than 70 for large-scale clinical production, and has achieved FDA DMF registration for its products [12]. Group 4: Commitment to Research and Development - Dr. Lantian continues to prioritize research, leading his team in publishing multiple preprints and addressing common design flaws in laboratory-made plasmids [14][16]. - The introduction of the miniVec™ plasmid system represents a significant innovation, enhancing safety and reducing production costs while being more suitable for clinical applications [16]. Group 5: Social Responsibility and Vision - Yunzhou Biotech actively contributes to the scientific community by providing free research tools, such as the VectorBee software, and engaging in collaborations to support rare disease treatments [18]. - The company's vision, as articulated by Dr. Lantian, is to leverage scientific advancements to improve the world, reflecting a commitment to both innovation and social impact [18].